title: Cabozantinib and prostate cancer: inhibiting seed and disrupting soil?
abstract: Treatment with cabozantinib, an inhibitor of MET and VEGFR2 signaling, has demonstrated clinical benefit in early trials in men with metastatic prostate cancer. Preclinical evidence suggests that cabozantinib can kill cancer cell seeds while disrupting angiogenesis and stromal cells in the metastatic soil.
authors.affiliation: Authors' Affiliation: Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts.
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Lee
authors.forename: Matthew R
authors.initials: MR
authors.lastname: Smith
mesh_terms: D000813:Anilides / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001859:Bone Neoplasms / Q000556:secondary*; D049109:Cell Proliferation / Q000187:drug effects*; D006801:Humans; D008297:Male; D010006:Osteoblasts / Q000187:drug effects*; D011471:Prostatic Neoplasms / Q000473:pathology*; D011725:Pyridines / Q000494:pharmacology*
chemical_list: D000813:Anilides; D000970:Antineoplastic Agents; D011725:Pyridines; C558660:cabozantinib